Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience
2024
Commentary on Burosumab for Hypophosphatemic Rickets
Commentary
Author Information
Author(s): Frank Rutsch, Isidro B. Salusky, Carlos R. Ferreira
Primary Institution: Muenster University Children’s Hospital
Conclusion
The use of burosumab in treating autosomal recessive hypophosphatemic rickets type 2 should be approached with caution due to potential cardiovascular risks.
Supporting Evidence
- Burosumab treatment may worsen arterial calcifications in some patients.
- Many patients with autosomal recessive hypophosphatemic rickets type 2 may have cardiovascular involvement.
- Current imaging techniques may miss early vascular calcifications in children.
Takeaway
This article talks about a medicine called burosumab that helps kids with a bone disease, but it warns that it might cause heart problems.
Potential Biases
There is a potential bias due to the author's conflict of interest with grant support and consultancy fees from Inozyme Pharma.
Limitations
The commentary highlights that the findings are based on a case report and may not apply to all patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website